Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06565078

A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency

Sponsor: Takeda

View on ClinicalTrials.gov

Summary

This study is a retrospective database study in Japan to evaluate the safety of Immune Globulin Subcutaneous (Human), 20% Solution in participants with primary immunodeficiency disease (PID). This survey will conduct in use of medical database called PIDJ2.

Official title: Post-marketing Database Survey: A Cohort Study to Evaluate the Safety of Cuvitru in Patients With Primary Immunodeficiency Using the PIDJ2 (Primary Immunodeficiency Database in Japan) Registry

Key Details

Gender

All

Age Range

Any - Any

Study Type

OBSERVATIONAL

Enrollment

100

Start Date

2025-02-17

Completion Date

2030-07-31

Last Updated

2026-02-20

Healthy Volunteers

No

Interventions

DRUG

Immune Globulin Subcutaneous (Human), 20% Solution

CUVITRU 20% Solution

Locations (1)

Takeda selected site

Tokyo, Tokyo, Japan